Advanz Has Six Deals In The Works As It Cuts Its Losses
Executive Summary
Advanz Pharma’s business development team is busty assessing potential deals as the recapitalized company works towards restoring profitability on an eroding revenues base.
You may also be interested in...
Advanz Sees Mumbai Center As Strategic Strength
Using its Indian back-office function to realize synergies from acquired sales and marketing assets in western Europe forms a key part of Advanz Pharma’s growth strategy.
Deal Watch: Themis Leverages Measles Vector Platform In Collaboration With Merck & Co.
In its first big pharma deal, Austrian biotech will develop experimental vaccines for Merck against an undisclosed target. Innovent licenses Chinese rights to Lilly diabetes candidate, while Novartis gets option to Iconic’s preclinical ophthalmology program.
UK's CMA Goes After Advanz, Morningside And Alliance On Nitrofurantoin
The UK’s Competition and Markets Authority has issued a statement of objections to Advanz, Morningside and wholesaler Alliance Healthcare after provisionally finding that the firms broke competition law by arranging to carve up the UK market for nitrofurantoin.